Investments (#)
Investments (USD)
Transactions
Recent transactions in the domain of 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Country | Funding round | Date | |
|---|---|---|---|---|
|
Judo Bio Inc Developer of oligonucleotide medicines delivered to the kidney. |
United States | Series A USD 100,000,000 (USD 100,000,000) |
7 Oct 2024 |
|
Neurelis Inc Neuroscience company. |
United States | Series D USD 114,000,000 (USD 114,000,000) |
10 Mar 2021 |
|
Maridose LLC Biotech - Cannabis R&D. We are a US DEA licensed manufacturer of Schedule 1 drugs. |
United States | Pre Seed USD 150,000 (USD 150,000) |
1 Jan 2021 |
|
Gilgamesh Pharmaceuticals Inc Novel psychedelic-Inspired therapeutics for treating mental illness. |
United States | Seed |
31 Dec 2019 |
|
3-V Biosciences Inc Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. |
United States | Series B USD 30,000,000 (USD 30,000,000) |
10 Jul 2019 |
|
Shire PLC |
Ireland | Acquisition |
8 Jan 2019 |
|
Vyome Biosciences Pvt Ltd Developer of medicines for treating skin diseases caused by resistant microbes. |
India | Series C USD 14,000,000 (USD 14,000,000) |
23 Aug 2016 |
|
Arcis Biotechnology Holdings Ltd |
United Kingdom | N/A GBP 2,500,000 at GBP 12,500,000 valuation. |
17 Feb 2016 |
|
FunkSac LLC Provider of customer services and compliant packaging solutions for the legal cannabis industry; both medical and recreational markets. |
N/A |
3 Nov 2015 | |
|
23andMe Inc DNA testing and genome sequencing firm. |
United States | Series E USD 79,100,000 (USD 79,100,000) |
3 Jul 2015 |
|
3SBio Inc |
IPO HKD 5,510,000,000 (USD 710,680,000) |
5 Jun 2015 | |
|
|
Avanir Pharmaceuticals Inc A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. |
United States | Acquisition USD 3,500,000,000 (USD 3,500,000,000) at USD 3,500,000,000 (USD 3,500,000,000) valuation. |
1 Dec 2014 |
|
|
Omega Pharma Belgium NV Belgian pharmaceutical company manufacturing and marketing a wide range of over-the-counter products in 35 countries worldwide. |
Belgium | Acquisition USD 4,500,000,000 (USD 4,500,000,000) at USD 4,500,000,000 (USD 4,500,000,000) valuation. |
6 Nov 2014 |
|
|
InterMune Inc Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. |
United States | Acquisition USD 8,300,000,000 (USD 8,300,000,000) at USD 8,300,000,000 (USD 8,300,000,000) valuation. |
24 Aug 2014 |
|
Santaris Pharma A/S |
Denmark | Acquisition USD 450,000,000 (USD 450,000,000) at USD 450,000,000 (USD 450,000,000) valuation. |
4 Aug 2014 |
|
|
23andMe Inc DNA testing and genome sequencing firm. |
United States | Grant USD 1,400,000 (USD 1,400,000) |
19 Jul 2014 |
|
|
Shire PLC |
Ireland | Acquisition USD 54,800,000,000 (USD 54,800,000,000) at USD 54,800,000,000 (USD 54,800,000,000) valuation. |
18 Jul 2014 |
|
|
ViroPharma Inc Provider of life-saving medicines for life-threatening diseases. |
United States | Acquisition USD 495,000,000 (USD 495,000,000) at USD 495,000,000 (USD 495,000,000) valuation. |
23 Jun 2014 |
|
Merck & Co |
United States | Acquisition USD 14,200,000,000 (USD 14,200,000,000) at USD 14,200,000,000 (USD 14,200,000,000) valuation. |
6 May 2014 |
|
|
Arecor Ltd Developer of technology that is used in the formulation of biopharmaceuticals. |
United Kingdom | N/A |
31 Dec 2013 |
|
|
ViroPharma Inc Provider of life-saving medicines for life-threatening diseases. |
United States | Acquisition USD 4,200,000,000 (USD 4,200,000,000) at USD 4,200,000,000 (USD 4,200,000,000) valuation. |
10 Nov 2013 |
|
|
Zosano Pharma Inc |
United States | Debt USD 3,030,000 (USD 3,030,000) |
19 Sep 2013 |
|
|
3-V Biosciences Inc Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. |
United States | Series C USD 20,000,000 (USD 20,000,000) |
21 Jun 2013 |
|
|
Warner Chilcott Corp |
United States | Acquisition USD 8,500,000,000 (USD 8,500,000,000) at USD 8,500,000,000 (USD 8,500,000,000) valuation. |
20 May 2013 |
|
|
Tokai Pharmaceuticals Inc Developer of prostate cancer drugs |
United States | Series E USD 35,000,000 (USD 35,000,000) |
15 May 2013 |
|
|
Trevena Inc |
United States | Series C USD 60,000,000 (USD 60,000,000) |
10 May 2013 |
|
|
Allecra Therapeutics Developer of antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria |
Series A EUR 15,000,000 |
19 Apr 2013 | |
|
|
Aquinox Pharmaceuticals Inc Developer of small molecule therapeutics for the treatment of inflammatory disease |
Canada | Series C USD 18,000,000 (USD 18,000,000) |
4 Apr 2013 |
|
|
Aquinox Pharmaceuticals Inc Developer of small molecule therapeutics for the treatment of inflammatory disease |
Canada | Series C |
4 Apr 2013 |
|
|
Kala Pharmaceuticals Inc Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases |
United States | Series A |
28 Feb 2013 |
|
|
Kala Pharmaceuticals Inc Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases |
United States | Series A USD 11,500,000 (USD 11,500,000) |
28 Feb 2013 |
|
|
DecImmune Therapeutics Inc Developer of antibodies to reduce tissue damage and improve ventricular function associated with myocardial infarction |
United States | Venture USD 2,250,000 (USD 2,250,000) |
27 Feb 2013 |
|
|
Quotient Biodiagnostics Holdings Ltd |
United Kingdom | Venture USD 5,000,000 (USD 5,000,000) |
27 Feb 2013 |
|
|
Venturepharma Group Provider of an innovative specialty pharmaceutical company that operates in China. |
China | N/A |
31 Dec 2012 |
|
|
3-V Biosciences Inc Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. |
United States | Venture USD 8,089,000 (USD 8,089,000) |
1 Oct 2012 |
|
|
Principia Biopharma Discoverer and developer of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. |
United States | Series A |
1 Oct 2012 |
|
|
New Haven Pharmaceuticals Inc Specialty pharmaceuticals company developing proprietary prescription pharmaceuticals. |
United States | Series A |
1 Oct 2012 |
|
|
Principia Biopharma Discoverer and developer of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. |
United States | Series A |
1 Oct 2012 |
|
|
Principia Biopharma Discoverer and developer of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. |
United States | Series A |
1 Oct 2012 |
|
|
Micro Interventional Devices Inc Developer of disruptive technologies for use in percutaneous and minimally invasive structural heart repair |
United States | Debt |
1 Aug 2012 |
|
|
Coferon Inc Develops orally active drugs that act like small drug molecules, can permeate cell membranes, and once inside, can assemble into larger molecules |
United States | Series B |
1 Jul 2012 |
|
|
Coferon Inc Develops orally active drugs that act like small drug molecules, can permeate cell membranes, and once inside, can assemble into larger molecules |
United States | Series B |
1 Jul 2012 |
|
|
Coferon Inc Develops orally active drugs that act like small drug molecules, can permeate cell membranes, and once inside, can assemble into larger molecules |
United States | Series B |
1 Jul 2012 |
|
|
Juventas Therapeutics Inc |
United States | Series B |
1 Jul 2012 |
|
|
Juventas Therapeutics Inc |
United States | Series B |
1 Jul 2012 |
|
|
Juventas Therapeutics Inc |
United States | Series B |
1 Jul 2012 |
|
|
Juventas Therapeutics Inc |
United States | Series B |
1 Jul 2012 |
|
|
Oxford Immunotec Ltd |
United Kingdom | Venture USD 28,000,000 (USD 28,000,000) |
18 Jun 2012 |
|
|
Avanir Pharmaceuticals Inc A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. |
United States | Debt |
1 Jun 2012 |
|
|
Gemmus Pharma Inc Developer of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. |
United States | Series A |
1 Jun 2012 |
Companies
Best funded companies in the domain of 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products
Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.
Belgian pharmaceutical company manufacturing and marketing a wide range of over-the-counter products in 35 countries worldwide.
A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.
Novel small molecule, receptor-specific therapeutics company for the treatment of central nervous system, cardiovascular and renal diseases.
Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases.
Developer of small molecule therapeutics for the treatment of inflammatory disease
Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases
Developer of medicines for treating skin diseases caused by resistant microbes.
Developer of antibodies to reduce tissue damage and improve ventricular function associated with myocardial infarction
Biotech - Cannabis R&D. We are a US DEA licensed manufacturer of Schedule 1 drugs.
Identifying new uses for established drugs. Arakis merged with Sosei Co in August 2005.
Develops a Web-based blood-pressure monitoring and management system for the patients with chronic diseases
Investors
Top investors in the domain of 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Investor | Profile | Country | Investments | |
|---|---|---|---|---|
|
New Enterprise Associates Inc | Global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. | United States | 104 |
|
Alta Partners LP | Venture capital firm based in San Francisco which invests primarily in biotechnology and life science companies. | United States | 58 |
|
Domain Associates LLC | Venture capital firm focused on life sciences companies. | United States | 49 |
|
Healthcare Ventures LLC | Venture capital firm focused on life sciences companies in pre-clinical and early clinical stage. | United States | 48 |
|
Venrock Associates | The venture capital arm of the Rockefeller Family. | United States | 37 |
|
Frazier Healthcare Ventures | Investment firm providing growth and venture capital to healthcare companies. | United States | 35 |
|
OrbiMed Advisors LLC | American investment firm focused on making public and private investments in the healthcare and biotechnology industries. | United States | 34 |
|
Novartis Services Inc | United States | 31 | |
|
Hercules Technology Growth Capital Inc | Specialised finance company providing debt and equity growth capital to technology-related companies at all stages of development. | United States | 29 |
|
MPM Capital | United States | 28 | |
|
Vivo Ventures LLC | United States | 24 | |
|
Sanderling Ventures | United States | 24 | |
|
Kleiner Perkins Caufield & Byers LLC | Venture capital firm. | United States | 24 |
|
Essex Woodlands Health Ventures Inc | United States | 24 | |
|
Versant Ventures Management LLC | Venture capital firm focused on making investments in the healthcare and biotechnology industries. | United States | 22 |
|
Johnson & Johnson Innovation LLC | Accelerator of early-stage innovation worldwide that forms collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. | United States | 22 |
|
CHL Medical Partners | Venture capital firm focused on early-stage healthcare sectors. | United States | 22 |
|
ARCH Venture Partners LP | Venture capital firm providing seed and early stage capital, with a special expertise in co-founding and building technology firms from startup | United States | 21 |
|
InterWest Partners | Diversified venture capital firm based in Silicon Valley. | United States | 21 |
|
Bay City Capital LLC | United States | 20 | |
|
MPM Asset Management LLC | United States | 20 | |
|
Pappas Ventures | United States | 20 | |
|
Sutter Hill Ventures LP | Private equity firm based in Palo Alto, Clifornia. | United States | 19 |
|
Polaris Venture Partners Inc | Multistage venture capital investors with focus Technology, Healthcare and Consumer | United States | 19 |
|
Delphi Ventures Inc | Venture capital firm with a focus on early stage investing in medical devices and biotechnology | United States | 19 |
|
BioAdvance - Biotechnology Greenhouse Corporation of Southeastern Pennsylvania | United States | 18 | |
|
Quaker BioVentures Inc | United States | 18 | |
|
ProQuest Investments | United States | 17 | |
|
Thomas McNerney & Partners LLC | Healthcare venture firm. | United States | 17 |
|
Novartis Venture Funds | The corporate venturing arm of Novartis. | Switzerland | 17 |
|
Canaan Partners | Venture capital firm with a focus on early stage technology and healthcare companies | United States | 16 |
|
Montreux Equity Partners | United States | 16 | |
|
TPG Growth LLC | The middle market and growth equity investment platform of TPG. | United States | 16 |
|
NGN Capital LLC | United States | 16 | |
|
HBM BioVentures AG | Switzerland | 16 | |
|
SR One Ltd | The venture capital unit of GlaxoSmithKline | United States | 16 |
|
Third Rock Ventures LLC | Venture capital firm focused on building healthcare companies | United States | 16 |
|
TPG Capital LP | Private equity firm | United States | 16 |
|
Prospect Venture Partners | Venture capital firm | United States | 16 |
|
Ben Franklin Technology Partners of Southeastern Pennsylvania | Initiative of the Pennsylvania Department of Community and Economic Development. | United States | 16 |
|
Sofinnova Ventures Inc | United States | 16 | |
|
Lilly Ventures | United States | 15 | |
|
Red Abbey Venture Partners LLC | United States | 15 | |
|
Astellas Venture Management LLC | United States | 15 | |
|
New Leaf Venture Partners | United States | 15 | |
|
Asset Management Co Venture Capital | Early-stage venture capital firm investing in digital health. | United States | 14 |
|
Rho Capital Partners | Venture capital firm that actively invests in companies related to technology, new media, cleaning technology and healthcare. | United States | 14 |
|
Skyline Ventures | Life Sciences venture capital firm | United States | 14 |
|
Bessemer Venture Partners | Early stage venture capital firm. | United States | 14 |
|
TVM Capital Corp | United States | 13 |
Acquirers
Top acquirers in the domain of 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products
Industry map
2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products industry map
Valuations
2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products selected pre-money valuations (USD)
| Funding round | Median | Average | Minimum | Maximum | Sample size |
|---|---|---|---|---|---|
| Acquisition | 4,500,000,000 | 9,085,716,154 | 450,000,000 | 54,800,000,000 | 13 |
| 450,000,000 | 54,800,000,000 | 13 |